TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa Jamie Cooper, Narek Shaverdian, Biagio Ricciuti, Joao Victor Machado Alessi, Andrea De Giglio, Federica Pecci, Giuseppe Lamberti, Malini Marion Gandhi, Lynette M. Sholl, Mizuki Nishino, Andrea Ardizzoni, Rebecca Suk Heist, Kathryn C. Arbour, Adam Jacob Schoenfeld, Natalie I Vokes, Mark M. Awad
Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400036826